Russia sets new rules for distributors and pharmacies

8 April 2019

The Russian Parliament has announced plans to limit the maximum share of pharmaceutical distributors and pharmacies in the domestic market and to oblige the latter to allocate up to 50% of their sale ranges for domestic drugs, according to recent statements by an official spokesman of the Russian Ministry of Health and members of the Russian Parliament (State Duma), reports The Pharma Letter’s local correspondent.

According to Sergei Neverov, a member of the Russian Duma and one of the main initiators of the latest state proposals, currently the share of domestic drugmakers in the Russian pharmaceutical market continues to be at low level. In addition, in recent months, the market has faced with a problem of a shortage of some vital drugs, as many global producers suspended their further supplies to Russia, due to low profits.

In the case of pharmacy chains, according to the Ministry of Health, in recent years the number of complaints about their activities from producers has significantly increased.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK